You are here

Keytruda

Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China

Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China

Fierce Pharma

Bristol-Myers Squibb

PD-1 inhibitors

Flag link:

FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer

FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer

Pharmaceutical Business Review

esophageal cancer

gastroesophageal cancer

Flag link:

Merck gets positive CHMP opinion for Keytruda as first-line treatment for dMMR colorectal cancer

Merck gets positive CHMP opinion for Keytruda as first-line treatment for dMMR colorectal cancer

Pharmaceutical Business Review

colorectal cancer

Flag link:

Merck's Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq?

Merck's Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq?

Endpoints

triple negative breast cancer

Flag link:

Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?

Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?

BioSpace

clinical trials

advanced renal cell carcinoma

Flag link:

Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC

Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC

Endpoints

clinical trials

non-small cell lung cancer

Flag link:

Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer

Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer

Fierce Pharma

priority review

non-small cell lung cancer

Flag link:

Sanofi to Evaluate THOR-707 with Merck's Checkpoint Inhibitor Keytruda

Sanofi to Evaluate THOR-707 with Merck's Checkpoint Inhibitor Keytruda

BioSpace

Flag link:

Merck raises annual profit outlook as Keytruda drives profit beat

Merck raises annual profit outlook as Keytruda drives profit beat

CNBC

Flag link:

Merck touts new data for Keytruda combos in NSCLC at North American conference

Merck touts new data for Keytruda combos in NSCLC at North American conference

Endpoints

clinical trials

non-small cell lung cancer

Flag link:

FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL

FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL

Pharmaceutical Business Review

Hodgkin's lymphoma

Flag link:

Sensei raises $29M to advance anti-cancer bacteriophage pipeline

Sensei raises $29M to advance anti-cancer bacteriophage pipeline

Fierce Biotech

Sensei Biotherapeutics

Flag link:

ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study

ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study

BioSpace

head and neck cancer

Flag link:

ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question

ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question

Fierce Pharma

triple negative breast cancer

Flag link:

ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show

ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show

Fierce Pharma

colorectal cancer

Flag link:

ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer

ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer

Fierce Pharma

metastatic bladder cancer

Flag link:

ESMO: Alkermes' major I-O hope sees progress across early cancer tests

ESMO: Alkermes' major I-O hope sees progress across early cancer tests

Fierce Biotech

immuno-oncology

Flag link:

Highlight Therapeutics trials second-line melanoma combo after immunotherapy fails

Highlight Therapeutics trials second-line melanoma combo after immunotherapy fails

Pharmaforum

Highlight Therapeutics

Flag link:

WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?

WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?

Fierce Pharma

Innovent Biologics

non-small cell lung cancer

Flag link:

NovoCure, Merck Team Up on Phase II Lung Cancer Trial

NovoCure, Merck Team Up on Phase II Lung Cancer Trial

BioSpace

clinical trials

tumor treating fields

non-small cell lung cancer

Flag link:

Pages